Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presents with established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria~* Active psoriatic arthritis (PsA) defined as the presence of at least 3 tender and at least 3 swollen joints~* Presence of active psoriatic skin lesion or a personal history of plaque psoriasis (Ps)~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Current or prior use of biologic agents for treatment of Ps or PsA~* Inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (DMARDs)~* Current use of more than one conventional DMARD~* Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than psoriatic arthritis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab Q2W (Type: EXPERIMENTAL): Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
- Ixekizumab Q4W (Type: EXPERIMENTAL): Administered by 80 mg SC injection every 4 weeks (Q4W).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
- Adalimumab Q2W (Type: ACTIVE_COMPARATOR): Administered by 40 mg SC injection Q2W.

Based on this trial design, predict the completion outcome and termination type (if applicable).